Takeda Pharmaceutical
300 hedge funds and large institutions have $1.38B invested in Takeda Pharmaceutical in 2023 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 109 increasing their positions, 67 reducing their positions, and 22 closing their positions.
517% more call options, than puts
Call options by funds: $37.8M | Put options by funds: $6.12M
114% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 22
63% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 67
30% more capital invested
Capital invested by funds: $1.06B → $1.38B (+$319M)
7% more funds holding
Funds holding: 281 → 300 (+19)
1.2% more ownership
Funds ownership: 4.3% → 5.5% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$174M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$57.2M |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$27.1M |
| 4 |
Millennium Management
New York
|
+$25.5M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$8.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$45.3M |
| 2 |
VanEck Associates
New York
|
-$12.2M |
| 3 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
-$4.56M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.04M |
| 5 |
CCM
Causeway Capital Management
Los Angeles,
California
|
-$3.2M |
TAK Hedge Fund Activity: Q1 2023 in Review
300 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2023, worth a combined $1.38B — up 30% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new TAK positions and 22 closed out — a net gain of 25 holders — while 109 added to existing stakes and 67 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $174M. The largest seller was Arrowstreet Capital, cutting an estimated $45.3M.
- 300 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2023, up from 281 in Q4 2022.
- Funds reported $1.38B of Takeda Pharmaceutical stock for Q1 2023, up 30% quarter-over-quarter.
- 47 funds opened new Takeda Pharmaceutical positions in Q1 2023 and 22 closed out, a net change of +25 holders.
- The largest Takeda Pharmaceutical buyer in Q1 2023 was Capital Research Global Investors, an estimated $174M added.
- The largest Takeda Pharmaceutical seller in Q1 2023 was Arrowstreet Capital, an estimated $45.3M sold.
Based on aggregated 13F filings for Q1 2023.